US FDA’s Foreign Data Policy Faces Its Greatest Test From Chinese PD-1/L1 Inhibitors
The swift rise of China’s oncology R&D has put at least four novel applications before FDA with pivotal data generated only in China.
The swift rise of China’s oncology R&D has put at least four novel applications before FDA with pivotal data generated only in China.